Invited Speakers:
Program:
IN VITRO HEMATOTOXICOLOGY, DRUG DEVELOPMENT AND
REGULATORY APPROVAL-CS696
Organizers: Martin J. Murphy, Jr.-Hipple Cancer Rsch Ctr and
Ralph E. Parchment-Food & Drug Administration
May 4-10, 1996; Bethesda, Maryland
Sat. 5/4-Orientation-KEYNOTE ADDRESS: R. Parchment, Food & Drug Admin, "Overview of
the Meeting and Consensus Questions"
Sun. 5/5-THE DEVELOPMENT OF IN VITRO HEMATOTOXICOLOGY I: N. Nicola , Walter
& Eliza Hall Inst Med, "The Biological Nature of Myeloid Colonies and Its Dependency Upon the
Cytokine Milieu"; F. Valeriote , Wayne State Univ, "In vivo Drug Toxicity to Clonogen ic
Subpopulations of the Myeloid and Erythroid Lineage"; M. Murphy, Hipple Cancer Rsch Ctr,
"Development of in vitro Systems for Hematotoxicity Measurements"; C. Grieshaber , Food & Drug
Administration, "In vitro Hematotoxicity Testing to Refine Animal To xicology"-POSTER SESSION
1-A COMPARISON OF IN VITRO AND IN VIVO HEMATOPOIESIS I: Speaker to be
Announced; B. Palsson , Aastrom Biosciences, "Cytokinetics of Human Hematopoiesis under
Expansion and Homeostatic Conditions in Perfusion Culture Systems"
Mon. 5/6-A COMPARISON OF IN VITRO AND IN VIVO HEMATOPOIESIS II: E.
Barbera-Guillem, Hipple Cancer Rsch Ctr, "Hematopoiesis in Microcapillary Cultures for
Automated Analyses"; A. Gewirtz, Univ Pennsylvania, "Does in vitro Megakaryocytopoiesis Relate
to Pl atelet Production in vivo?"; Speaker to be Announced; J. Bueren, CIEMAT-Madrid, "Bone
Marrow Progenitors and Functional Hematopoiesis"-POSTER SESSION 2-IN VITRO
SYSTEMS USED FOR HEMATOTOXICITY TESTING: PROS AND CONS: D. Volpe, Food
& Drug Admin, "Clonog enic Assays Optimized for Hematotoxicology"; Y. Kalechman, Bar Lian
Univ-Israel,"In vitro Assesment of Toxicity to Stromal Function and Survival"; S. Heimfeld, CellPro,
"Development of Cytokine-Based Assays for the Quantitative Measurement of Primitive Hu man
Progenitor Cell Subsets"; R. Ploemacher, Erasmus Univ, "Hematotoxicity Evaluations in
Homeostatic Stroma Supported Cultures"
Tue. 5/7-DEALING WITH TROUBLESOME MECHANISMS OF HEMATOTOXICITY IN
VITRO: J. Tomaszewski , Nat'l Inst Hlth, "Non-Cytotoxic Drugs and Biologics"; J. San Roman ,
Advanced Tissue Sciences, "In vitro Systems for Hematotoxicity Assessment of Pro-Toxicants"; J.
Collins , Food & Drug Administration, "In vitro Metabolic Systems for Inter-Species Comparisons";
T. Burke, Ohio State Univ, "Species-Specific Pharmacodynamic Differences for Camptothecin
Drugs Measured in vitro"-POSTER SESSION 3-IN VITRO MODELING AND DR UG
METABOLISM BY BONE MARROW CELL TYPES: D. Ross , Univ Colorado-Denver,
"Stromal Production of Benzene Metabolites"; George Kalf, Thomas Jefferson Univ,
"Benzene-Induced Bone Marrow Cells Depression Caused by Inhibition of the Conversion of
Pre-Interleu kins -1 alpha and -1 beta to Active Cytokines by Hydroquinone, A Biological Reactive
Intermediate of Benzene"; J.W. Flesher, Univ Kentucky, "Bioactivation of Pro-Carcinogens by
Human Bone Marrow"; M. Trush, Johns Hopkins Sch Hygiene & Public Hlth, "In vit ro Studies on
the Mechanism of Benzapyrene - Induced Toxicity to the Stromal Microenvironment"
Wed. 5/8-POTENTIAL APPLICATIONS OF IN VITRO HEMATOTOXICOLOGY I: DRUG
DISCOVERY AND PRECLINICAL DEVELOPMENT: J. Cardier, Hipple Cancer Rsch Ctr, "In
vitro Megakaryocyte Toxicity: Evaluation From Primitive Hematopoietic Cells"; A. Deldar, Eli Lilly
& Com pany, "Potential Applications of in vitro Hematopoietic Progenitor Assays in Pharmaceutical
Industries"; Speaker to be Announced; M. Alley , Nat'l Cancer Inst, "Hollow Fiber Implants for
Monitoring Drug Toxicity to Clonogens from Tumors and Bone Marrow"-P OSTER SESSION
4-POTENTIAL APPLICATIONS OF IN VITRO HEMATOTOXICOLOGY II: BRIDGING
PRECLINICAL AND CLINICAL STUDIES: R. Parchment, Food & Drug Admin, "Toward
Preclinical Predicttion of the Exposure Level of Cytoreductive Agents that will Cause Grade 4 Neu
tropenia"; D. Parent-Massin, Ecole Supˇriure de Microbiologie et Sˇcuritˇ Alimentaire,
"Clonogenic Assays Optimized for Detection of Hematotoxic Food Contaminants"; P. LoRusso,
Harper Hosp, "Continued Dosing of Acetyldinaline through Grade 3 Cytopenia Bas ed on
Preclinical Data"; Speaker to be Announced, "In vitro Data and Evaluation of Antineoplastic INDs"
Thur. 5/9-POTENTIAL APPLICATIONS OF IN VITRO HEMATOTOXICOLOGY III:
EVALUATION AND APPROVAL OF NEW MOLECULAR ENTITIES: Speaker to be
Announced, "The Clinical Utility of in vitro Hematotoxicology for Drug Development in Medical
Oncology"; John Bloom , Eli Lilly & Co, "Routine in vitro Hematotoxicology: To Use or Not to
Use?"; G. Schoeters , VITO, "The European Community's Initiative on in vitro Hematotoxicology";
Speaker to be Announced, "In vitro Human Toxicology and Regulation of Potential Environmenta l
Contaminants". Speaker to be Announced, "Perspectives on in vitro Human Toxicology and
Evaluation of NMEs"-CONSENSUS SESSION WITH FLOOR DISCUSSION-Banquet (Please
note: There are NO POSTERS on banquet day.)
Fri. 5/10-Departure
Registration :
Cambridge Symposia
1037 Chestnut Street
Newton Upper Falls, MA 02164
Phone:(617)630-1399
Fax:(617)630-1395
Deadline for Abstracts: January 10, 1996
Email for Requests and Registration: symposia@cambridge.org